Studies on the composition and elimination of circulating immune complexes in leukaemia. 1980

S R Hollán, and G Füst, and A Mód, and E Puskás, and Nguyen Chi Phi

Longitudinal studies for the detection of circulating immune complexes (CIC-s) were performed in leukaemic patients using three methods in parallel. Results of these studies indicated that immune complexes in leukaemia are heterogeneous and their composition changes in the course of the disease. These results were supported by the changes in the concentration of a complement component (C1) and in the IgG subclasses in the immune complex-enriched fraction prepared by polyethylene glycol precipitation from different serum samples of individual patients with leukaemia. CIC-s from leukaemic patients are normally engulfed by granulocytes of healthy donors. The phagocytic capacity of leukaemic blast cells is hampered. The phagocytic activity through Fc and C3 receptors of peripheral mononuclear cells of leukaemic patients did not run parallel. On the basis of these studies it may be surmised that the total phagocytic capacity of the leukaemic patients cannot keep pace with the increased rate of immune complex formation.

UI MeSH Term Description Entries
D007074 Immunoglobulin G The major immunoglobulin isotype class in normal human serum. There are several isotype subclasses of IgG, for example, IgG1, IgG2A, and IgG2B. Gamma Globulin, 7S,IgG,IgG Antibody,Allerglobuline,IgG(T),IgG1,IgG2,IgG2A,IgG2B,IgG3,IgG4,Immunoglobulin GT,Polyglobin,7S Gamma Globulin,Antibody, IgG,GT, Immunoglobulin
D007141 Immunoglobulin Fc Fragments Crystallizable fragments composed of the carboxy-terminal halves of both IMMUNOGLOBULIN HEAVY CHAINS linked to each other by disulfide bonds. Fc fragments contain the carboxy-terminal parts of the heavy chain constant regions that are responsible for the effector functions of an immunoglobulin (COMPLEMENT fixation, binding to the cell membrane via FC RECEPTORS, and placental transport). This fragment can be obtained by digestion of immunoglobulins with the proteolytic enzyme PAPAIN. Fc Fragment,Fc Fragments,Fc Immunoglobulin,Fc Immunoglobulins,Ig Fc Fragments,Immunoglobulin Fc Fragment,Immunoglobulins, Fc,Immunoglobulins, Fc Fragment,Fc Fragment Immunoglobulins,Fc Fragment, Immunoglobulin,Fc Fragments, Ig,Fc Fragments, Immunoglobulin,Fragment Immunoglobulins, Fc,Fragment, Fc,Fragments, Ig Fc,Immunoglobulin, Fc
D007938 Leukemia A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006) Leucocythaemia,Leucocythemia,Leucocythaemias,Leucocythemias,Leukemias
D009000 Monocytes Large, phagocytic mononuclear leukocytes produced in the vertebrate BONE MARROW and released into the BLOOD; contain a large, oval or somewhat indented nucleus surrounded by voluminous cytoplasm and numerous organelles. Monocyte
D010587 Phagocytosis The engulfing and degradation of microorganisms; other cells that are dead, dying, or pathogenic; and foreign particles by phagocytic cells (PHAGOCYTES). Phagocytoses
D011971 Receptors, Immunologic Cell surface molecules on cells of the immune system that specifically bind surface molecules or messenger molecules and trigger changes in the behavior of cells. Although these receptors were first identified in the immune system, many have important functions elsewhere. Immunologic Receptors,Immunologic Receptor,Immunological Receptors,Receptor, Immunologic,Receptors, Immunological
D003172 Complement C1 The first complement component to act in the activation of CLASSICAL COMPLEMENT PATHWAY. It is a calcium-dependent trimolecular complex made up of three subcomponents: COMPLEMENT C1Q; COMPLEMENT C1R; and COMPLEMENT C1S at 1:2:2 ratios. When the intact C1 binds to at least two antibodies (involving C1q), C1r and C1s are sequentially activated, leading to subsequent steps in the cascade of COMPLEMENT ACTIVATION. C1 Complement,Complement 1,Complement Component 1,C1, Complement,Complement, C1,Component 1, Complement
D003176 Complement C3 A glycoprotein that is central in both the classical and the alternative pathway of COMPLEMENT ACTIVATION. C3 can be cleaved into COMPLEMENT C3A and COMPLEMENT C3B, spontaneously at low level or by C3 CONVERTASE at high level. The smaller fragment C3a is an ANAPHYLATOXIN and mediator of local inflammatory process. The larger fragment C3b binds with C3 convertase to form C5 convertase. C3 Complement,C3 Precursor,Complement 3,Complement C3 Precursor,Complement Component 3,Precursor-Complement 3,Pro-C3,Pro-Complement 3,C3 Precursor, Complement,C3, Complement,Complement, C3,Component 3, Complement,Precursor Complement 3,Precursor, C3,Precursor, Complement C3,Pro C3,Pro Complement 3
D006098 Granulocytes Leukocytes with abundant granules in the cytoplasm. They are divided into three groups according to the staining properties of the granules: neutrophilic, eosinophilic, and basophilic. Mature granulocytes are the NEUTROPHILS; EOSINOPHILS; and BASOPHILS. Granulocyte
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

S R Hollán, and G Füst, and A Mód, and E Puskás, and Nguyen Chi Phi
October 1981, British journal of haematology,
S R Hollán, and G Füst, and A Mód, and E Puskás, and Nguyen Chi Phi
February 1989, Nihon Jinzo Gakkai shi,
S R Hollán, and G Füst, and A Mód, and E Puskás, and Nguyen Chi Phi
January 2000, Meditsinskaia parazitologiia i parazitarnye bolezni,
S R Hollán, and G Füst, and A Mód, and E Puskás, and Nguyen Chi Phi
February 1989, Nihon Jinzo Gakkai shi,
S R Hollán, and G Füst, and A Mód, and E Puskás, and Nguyen Chi Phi
September 1978, International journal of cancer,
S R Hollán, and G Füst, and A Mód, and E Puskás, and Nguyen Chi Phi
September 1988, Journal of clinical & laboratory immunology,
S R Hollán, and G Füst, and A Mód, and E Puskás, and Nguyen Chi Phi
February 1978, Atherosclerosis,
S R Hollán, and G Füst, and A Mód, and E Puskás, and Nguyen Chi Phi
June 1978, Minerva medica,
S R Hollán, and G Füst, and A Mód, and E Puskás, and Nguyen Chi Phi
January 2014, Doklady. Biochemistry and biophysics,
S R Hollán, and G Füst, and A Mód, and E Puskás, and Nguyen Chi Phi
January 1982, Clinical and investigative medicine. Medecine clinique et experimentale,
Copied contents to your clipboard!